Local Lung Immune Response to Mycobacterium bovis Challenge after BCG and M. bovis Heat-Inactivated Vaccination in European Badger (Meles meles)

Can badger vaccination contribute to bovine TB control? A narrative review of the evidence

In parts of Europe, the European badger Meles meles acts as a wildlife host for Mycobacterium bovis, the causative agent of bovine tuberculosis (bTB). Options for reducing the risk of transmission of M. bovis from badgers to cattle include biosecurity measures, culling, and vaccination of badgers using the BCG vaccine. The use of vaccination as a control measure for tuberculosis (TB) in badgers has increased in recent years, with large-scale deployment in Ireland, and increasing use in England alongside a gradual phasing out of badger culling. Here we review evidence relating to the use of badger vaccination as a tool for controlling TB in badgers and cattle. Vaccination reduces the severity and progression of TB in badgers experimentally infected with M. bovis in laboratory studies, and significantly decreases the likelihood of naturally-acquired infection in free-living badgers in field trials. Modelling studies evaluating different strategies for controlling TB in badgers predict that badger vaccination will reduce TB prevalence in badger populations and lead to corresponding reductions in cattle herd disease incidence. While large scale field trials have not been undertaken to quantify the level of impact of badger vaccination on cattle bTB incidence in the UK, field studies in Ireland suggest that in some situations badger vaccination can result in beneficial disease outcomes in cattle which are comparable to those from badger culling. Attitudes to badger vaccination vary among stakeholder groups. Although members of the public are relatively positive about the benefits of vaccination, farmers are generally negative, due to concerns about practicality and effectiveness, along with a view that badger populations need to be controlled. The evidence published to date indicates that badger vaccination has the potential to contribute to the control of TB prevalence in wild badger populations and to form part of a wider strategy for controlling bTB. Future research should focus on investigating the effect of badger vaccination on bTB in cattle, along with understanding the impacts of vaccination in badgers in a broader range of ecological settings. Further understanding of the drivers of negative attitudes towards vaccination will nonetheless be crucial for incentivising and increasing the deployment of badger vaccination.

Wildlife Immune Responses to Mycobacterium bovis and to Bacille of Calmette-Guerin

Bovine tuberculosis (bTB) is a zoonotic bacterial disease presenting public health, veterinary, and economic threats around the globe. Although cattle producers rely on regular testing and management practices to minimize domestic herd exposure, wildlife species around the world continue to be the main reservoirs for disease. Wildlife reservoirs for bTB include the Eurasian badger (Meles meles) in Great Britain and Ireland, the brushtail possum (Trichosurus vulpecula) in New Zealand, wild boar (Sus scrofa) in Spain, as well as white-tailed deer (Odocoileus virginianus) in the United States and red deer (Cervus elaphus) in Spain. Although all reservoir species share the ability to infect cattle, they differ in transmission capability, disease pathogenesis, diagnostic detection, and vaccination strategies. In this review, bTB interactions with these wildlife reservoirs are discussed, illustrating the need to address bTB disease in wildlife hosts to achieve eradication in domestic livestock.

Advance in strategies to build efficient vaccines against tuberculosis

Tuberculosis is a chronic consumptive infectious disease, which can cause great damage to human and animal health all over the world. The emergence of multi-drug resistant strains, the unstable protective effect of Bacillus Calmette-Guérin (BCG) vaccine on adults, and the mixed infection with HIV all warn people to exploit new approaches for conquering tuberculosis. At present, there has been significant progress in developing tuberculosis vaccines, such as improved BCG vaccine, subunit vaccine, DNA vaccine, live attenuated vaccine and inactivated vaccine. Among these candidate vaccines, there are some promising vaccines to improve or replace BCG vaccine effect. Meanwhile, the application of adjuvants, prime-boost strategy, immunoinformatic tools and targeting components have been studied concentratedly, and verified as valid means of raising the efficiency of tuberculosis vaccines as well. In this paper, the latest advance in tuberculosis vaccines in recent years is reviewed to provide reliable information for future tuberculosis prevention and treatment.

Nonspecific protection of heat-inactivated Mycobacterium bovis against Salmonella Choleraesuis infection in pigs

Trained immunity is the capacity of innate immune cells to produce an improved response against a secondary infection after a previous unrelated infection. Salmonellosis represents a public health issue and affects the pig farming industry. In general, vaccination against salmonellosis is still facing problems regarding the control of distinct serovars. Therefore, we hypothesized that an immunostimulant based on heat inactivated Mycobacterium bovis (HIMB) could have an immune training effect in pigs challenged with Salmonella enterica serovar Choleraesuis (S. Choleraesuis) and decided to explore the amplitude of this non-specific immune response. For this purpose, twenty-four 10 days-old female piglets were randomly separated in three groups: immunized group (n = 10) received orally two doses of HIMB prior to the intratracheal S. Choleraesuis-challenge, positive control group (n = 9) that was only challenged with S. Choleraesuis, and negative control group (n = 5) that was neither immunized nor infected. All individuals were necropsied 21 days post-challenge. HIMB improved weight gain and reduced respiratory symptoms and pulmonary lesions caused by S. Choleraesuis in pigs. Pigs immunized with HIMB showed higher cytokine production, especially of serum TNFα and lung CCL28, an important mediator of mucosal trained immunity. Moreover, immunized pigs showed lower levels of the biomarker of lipid oxidation malondialdehyde and higher activity of the antioxidant enzyme superoxide dismutase than untreated challenged pigs. However, the excretion and tissue colonization of S. Choleraesuis remained unaffected. This proof-of-concept study suggests beneficial clinical, pathological, and heterologous immunological effects against bacterial pathogens within the concept of trained immunity, opening avenues for further research.